Congenital hypogonadotrophic hypogonadism (CHH) is a rare form of infertility caused by deficient secretion or action of gonadotrophin-releasing hormone. There is no consensus regarding the optimal approach to fertility treatment in CHH men. In most cases, appropriate hormonal treatment with human chorionic gonadotrophin with or without follicle stimulating hormone will induce testicular develo...

Effective contraception is necessary in countries where limiting population growth has become a public policy imperative. The main antigenic targets for contraceptive vaccine development can be listed as following: 1) sperm antigens, 2) zona pellucida antigens, 3) gonadotrophin-releasing hormone, 4) chorionic gonadotrophin, 5) other protein/peptide hormones (follicle-stimulating hormone, lutein...

Ovulation Induction and Oocyte Recovery Ovarian hyperstimulation was achieved using GnRH analogue (nafarelin acetate, Synarel®, Pfizer) along with human recombinant FSH (r-hFSH: Gonal-F®, MerckSerono) in a long down-regulation protocol. Starting gonadotrophin dose varied from 150-300 IU and was based on female age, body mass index, ovarian volume, basal FSH levels and the number of preantral fo...

A retrospective analysis was performed on 64 cycles stimulated with human menopausal gonadotrophin and/or pure follicle-stimulating hormone (FSH) and oestrogen (E2) levels. The increase in serum E2 on the day of HCG administration did not correlate (r = 0.05) with the number of preovulatory oocytes (preovs) or with an increase or decrease in serum FSH (r = 0.31). However, the change in serum FS...